MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
41.95
+0.42
+1.01%
After Hours: 41.95 0 0.00% 16:33 03/30 EDT
OPEN
41.82
PREV CLOSE
41.53
HIGH
42.25
LOW
41.57
VOLUME
2.10M
TURNOVER
--
52 WEEK HIGH
49.62
52 WEEK LOW
32.38
MARKET CAP
10.89B
P/E (TTM)
15.11
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EXEL last week (0323-0327)?
Weekly Report · 20h ago
Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)
TipRanks · 5d ago
Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
TipRanks · 5d ago
Recursion names Vicki Goodman chief medical officer effective April 6, 2026; David Mauro exits after about three years
Reuters · 5d ago
Weekly Report: what happened at EXEL last week (0316-0320)?
Weekly Report · 03/23 10:05
The Best Healthcare Stocks to Buy With $50 Right Now
The Motley Fool · 03/18 12:50
PJP: Healthcare Dashboard For March
Seeking Alpha · 03/17 09:12
Weekly Report: what happened at EXEL last week (0309-0313)?
Weekly Report · 03/16 10:05
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.